Page 275«..10 20..274275276 277..280 290..»

Category Archives: Stem Cell Therapy

Kurt May to Join International Stem Cell Corporation as Senior Vice President

Posted: June 26, 2011 at 4:05 pm

Andrey Semechkin, Ph.D., CEO of International Stem Cell Corporation (OTCBB:ISCOE) ("ISCO") announced today that Kurt May, a highly experienced senior business executive and biotechnology entrepreneur, is concluding his service as a faculty member at the University of San Diego's School of Business Administration and is joining ISCO as a Senior Vice President.

Mr. May's duties will include mergers and acquisitions and development of new international collaborations, and he will work directly with Dr. Semechkin in implementing the Company's business model of combining cutting-edge scientific research and building multiple revenue streams to support that research.

Prior to joining ISCO, Mr. May was a senior executive with GTE Corporation, a Fortune 50 company, where he enjoyed 23 years of progressive management experience. Mr. May then went on to serve as Executive Vice President and Chief Operating Officer with PriceSmart Inc. Since 2001 Mr. May has founded and led a privately owned biotech company, Psynomics Inc., as CEO. Psynomics Inc. is a spin out of the University of California San Diego, where Mr. May served as a faculty member and Assistant Dean of the Rady School of Management from 2005 until 2009.

"Mr. May strengthens an accomplished management team at ISCO, and I am delighted that we attracted a professional of his caliber to our Company," said ISCO'S CEO, Dr. Semechkin.

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements
Statements pertaining to anticipated developments, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, competition, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation
Andrey Semechkin, PhD
CEO & President
760-940-6383
aes@intlstemcell.com
or:
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com

Posted in Stem Cells, Stem Cell Therapy | Comments Off

Lou Gehrig's Disease (ALS): UCSD Team's Stem Cell Therapy Rationale

Posted: June 26, 2011 at 2:38 pm

(Part 3 of 8) Don Cleveland, Ph.D. spoke at the "Spotlight on Disease Team Awards: ALS," an educational event presented at the CIRM Governing Board meeting on June 23, 2010. Goldstein is a co-principle investigator of the CIRM ALS Disease Team and member of The Ludwig Institute

Go here to see the original:
Lou Gehrig's Disease (ALS): UCSD Team's Stem Cell Therapy Rationale

Posted in Stem Cell Therapy | Comments Off

TRANSPLANT VIEWS: Stem cell therapy used for diabetic patients

Posted: June 23, 2011 at 11:27 am

Stem cell therapy used for diabetic patients: "CHENNAI: Doctors in the city claim to have achieved a major breakthrough in saving the legs of several diabetic patients from amputation using stem cell therapy . ...

CHENNAI: Doctors in the city claim to have achieved a major breakthrough in saving the legs of several diabetic patients from amputation using stem cell therapy. Vascular surgeons from Vijaya Hospital, Vadapalani, along with stem cell experts from Nichi-In Centre for Regenerative Medicine (NCRM), claimed to have cured leg ulcers using stem cells from the patient’s own bone marrow.

The patients, who were initially advised to have their legs amputated to avoid spreading of infection and septicemia, were walking on their own feet, the doctors claimed.
Dr S R Subramanniyan, Chief Vascular Surgeon, Vijaya Hospital, told Express that the cases of Vimala (67), a long time diabetic, and Veeragovindaraj, in his late fifties, posed a challenge before them.

While Veeragovindaraj already had one leg amputated and was advised to cut off the other one to prevent spread of infection, Vimala had one limb severely infected and ready to be cut off. “In Veeragovindaraj’s case, we could not even do a bypass as his blood vessels did not have adequate length. We were fighting to save his only limb of which, he had already lost the heel and the forefoot. For him, turning on bed itself was arduous,” said Dr Subramanniyan.

Vimala’s case was also critical as the infection had spread up to her knees, he added. In both cases, the stem cells were drawn from their bone marrow and isolated before being auto transplanted into the ischemic area. In a couple of weeks, there were signs of rejuvenation. “While injecting, we kept tabs on the quantity of stem cells injected for standardisation. We even checked for infection indicators,” Dr Subramanniyan added. Gradually, the condition of the blood vessels improved and blood supply to the lower limbs also became better.

“Veeragovindaraj is now in Bangalore while Vimala is able to walk about in her house. These cases give hope to millions of diabetics in India,” Dr Samuel J K Abraham, Director, NCRM, told Express over phone from Yamanashi, Japan. This study on patients with severe uncontrolled diabetes, published in Cytotherapy, the official journal for the International Society for Cellular Therapy (ISCT), is claimed to possibly be the first such case in India.

Continue reading here:
TRANSPLANT VIEWS: Stem cell therapy used for diabetic patients

Posted in Diabetes, Stem Cell Therapy | Comments Off

Stem Cell Therapy for Multiple Sclerosis (MS patient)

Posted: June 23, 2011 at 3:23 am

http://www.cellmedicine.com

The rest is here:
Stem Cell Therapy for Multiple Sclerosis (MS patient)

Posted in Stem Cell Therapy | Comments Off

Heart Disease And Cardiac Failure: The Role Of Stem Cells …

Posted: June 23, 2011 at 3:23 am

Heart Disease And Cardiac Failure: The Role Of Stem Cells

Stem cell therapy for cardiac failure has astounded the medical profession and resulted in the immediate implementation of clinical trials to fast-track regulation and implementation. The available treatment protocol for cardiac failure has been used successfully since 2007 and is the same procedure that is to be followed in future FDA-approved clinical trials. Patients with extremely poor ejection fractions have responded well enough to return to a normal lifestyle with minimal medication needs.

Stem cell therapy and cardiac failure

Stem cell therapy is the latest tool in regenerative cardiac medical therapy. Its potential for use in cardiovascular disease has only recently been recognized in clinical trials. A randomized study was conducted in 20 patients to deploy stem cells as an adjuvant to conventional revascularization therapy in patients with congestive heart failure. 1

Injections of adult stem cells into damaged heart tissue significantly improved heart function in patients with severe congestive heart failure, according to results of the first prospective randomized trial of the experimental therapy. 4

The results were astounding in that this study proved that in the early stages of recovery the stem cell transplant group fared the same as the surgical group, but at one month post-treatment, the gap widened to show that the stem cell treated group started doing better and the surgical group stagnated. This carried through for the rest of the study period and by six months the stem cell treated group had improved an average of 46% as compared to only 35% in the surgically treated group.1 The head researcher for this study stated their findings provide the first convincing evidence that transplantation of adult stem cells that promote growth of blood vessels and heart muscle can be a viable treatment for congestive heart failure.4

It is now becoming widely accepted that stem cells can repair heart tissue and now the structure of clinical trials seems to be focused on how many and what type of cells to use and not whether this works or not. During the writing of this article the author noted 6 FDA-approved clinical trials currently recruiting patients. 2

In 2008, Mayo Clinic investigators have demonstrated that stem cells can be used to regenerate heart tissue to treat dilated cardiomyopathy, one of the causes of cardiac failure. Interesting to note here is that the responses also seemed to start after one month as in the first study mentioned above.3

We see that by using the correct stem cells augmented by RegAmp in a minimally invasive procedure we achieve the same results, which according to our track record, is, on average a 40% improvement over baseline after three months. These are the best results available today and are borne out by their similarity to results that have been attained in animal and human studies in FDA-approved clinical trials. We have not experienced any adverse events in any of our patients during this safe and effective procedure, which can be performed at any one of the Regenecell clinics worldwide.

Additional informaton can be found at http://www.regenecell.com

References:
1. Patel A N et al. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: A prospective randomized study. J Thor & Card Surgery. Vol 130, Issue 6, Pages 1631-1638 (December 2005).
2. Clinicaltrials.gov
3. Physorg.com
4. mirm.pitt.edu/news

Dr Jeff Peimer MBChB (UCT) is a medical doctor with extensive experience in regenerative medicine, mental health and emergency medicine. He is the medical director of Regenecell, a company specialising in stem cell treatments. Jeff is consulted extensively by patients and their families who need help evaluating stem cell treatment. His main area of interest is the treatment of severe disease and injury by using umbilical cord stem cells.
He lives in Cape Town with his wife and two sons.

Visit the Regenecell website for more on stem cell therapy or Jeff’s Facebook page here

Original post:
Heart Disease And Cardiac Failure: The Role Of Stem Cells ...

Posted in Stem Cell Therapy | Comments Off

Stem Cell Therapy for Stroke – Gary Steinberg, Stanford University

Posted: June 19, 2011 at 6:15 pm

(Part 2 of 3) Gary Steinberg, MD, Ph.D., spoke at the "Spotlight on Disease Team Awards: Sub-Cortical Stroke," an educational event presented at the CIRM Governing Board meeting on August 19, 2010. Steinberg is the principle investigator for the CIRM Stroke Disease Team

See the rest here:
Stem Cell Therapy for Stroke - Gary Steinberg, Stanford University

Posted in Stem Cell Therapy | Comments Off

International Stem Cell Corporation (ISCO) Announces That Donna Queen, Former President and CEO of ZO SKIN HEALTH, the Luxury Brand Created by Zein Obagi, MD, Has Joined ISCO Executive Team

Posted: June 19, 2011 at 4:09 pm

International Stem Cell Corporation (OTCBB:ISCOE) announced today that Donna Queen has joined ISCO's executive team. Ms. Queen will be primarily responsible for ISCO's wholly owned subsidiary Lifeline Skin Care's (Lifeline) brand identity and international marketing as well as broadening the range of Lifeline products currently available.

Prior to joining ISCO, Ms. Queen was President and CEO of ZO SKIN HEALTH® by Zein Obagi, MD. Dr. Obagi is the dermatologist who created the original Obagi Nu-Derm skincare system, which has since become the leading physician-dispensed brand of anti-aging skincare. Earlier Ms. Queen founded and led one of Virginia's largest advertising and marketing agencies, specializing in aesthetic and dermatological marketing and brand development.

Dr. Andrey Semechkin, President and CEO of ISCO, commented: "I'm very pleased that Ms. Queen has joined our team. Ms. Queen's industry experience and expertise particularly in marketing prescription-based products will be invaluable as we expand our skin care business and further enhance our line of products."

Ms. Queen adds, "I'm very excited to be joining such a dynamic, science-driven company. There have been no recent meaningful technological breakthroughs in skin care, but with ISCO's scientific leadership in stem cells and their knowledge of skin tissue physiology we have an opportunity to continue to deliver new and innovative treatments."

ISCO previously announced sales of approximately $1.1 million from the pilot direct-to-consumer launch of Lifeline's first two products, an anti-aging Day Serum and a Night Serum. These products were developed by ISCO's scientific research team in collaboration with internationally recognized cosmetics experts. The serums contain an extract from ISCO?s proprietary human parthenogenetic stem cells combined with antioxidants and botanically derived ingredients. Using these serums on a regular basis provides significant benefits to the skin including improvement in skin tone and elasticity and the improvement in the appearance of fine lines and wrinkles, results that have been independently established by clinical studies performed at industry-leading testing laboratories. The serums can be purchased by visiting Lifeline?s website at http://www.lifelineskincare.com and are also available at selected luxury spas and physicians' offices in the United States.

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements
Statements pertaining to anticipated developments, product development and marketing plans, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, competition, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, PhD
Vice President, ISCO
CEO, Lifeline Skin Care
ras@intlstemcell.com
or
Simon Craw, PhD
Vice President, ISCO
sc@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

Posted in Stem Cells, Stem Cell Therapy | Comments Off

International Stem Cell Corporation Discovers Method to Produce Uncontaminated Liver Cells: New Platform to Produce Various Cell Types Free From Undifferentiated, Potentially Tumorigenic, Cells

Posted: June 19, 2011 at 4:09 pm

International Stem Cell Corporation (OTCBB:ISCOE) announces the discovery of a novel, patent-pending technology to produce unlimited numbers of liver cells (hepatocytes) that are free of contamination with potentially dangerous undifferentiated cells. The technology is based on the natural, physiological properties of the cellular environment, and does not require any additional purification of the final product. The starting materials for the production are pluripotent stem cells, either ISCO's proprietary human parthenogenetic stem cells (hpSCs) or human embryonic stem cells (hESCs).

The technology is described in a new article that will appear in Cell Transplantation, the Regenerative Medicine Journal (currently the article is available only in electronic form). The published data also reinforce that hpSCs can provide the cellular material necessary for the implementation of cell-based therapies.

Marie Csete, M.D., Ph.D., co-author of the paper, said, "Derivation of differentiated cell products that are not contaminated with undifferentiated cells solves a major technical roadblock in the development of all pluripotent stem cell-based therapies because undifferentiated stem cells with tumorigenic potential can persist through long differentiation protocols. Therefore methods to generate pure differentiated cells for transplantation are critical for creating successful cell therapies. Furthermore, the elegant technology developed by ISCO scientists to enforce critical steps in differentiation illustrates the power and importance of basic engineering tools in stem cell biology."

Nikolay Turovets, Ph.D., Director of Research and Therapeutic Development at ISCO and co-author of the paper stated, "The technology discovered by our research team is based on reproducing features of the normal human embryonic microenvironment. The method uses a differentiation device that incorporates a three-dimensional extracellular matrix, combined with a porous membrane. Treatment of undifferentiated cells above the membrane using differentiation-directed proteins results in permitting the desired cells to migrate through the membrane into the matrix, where they further differentiate into functional hepatocytes."

Jeffrey Fair, M.D., liver transplant surgeon and Director of Translational Research for the Cedars-Sinai Comprehensive Transplant Center and Department of Surgery in Los Angeles, and co-author of the paper said, "Derivatives of HLA-homozygous hpSCs are likely to be significantly less susceptible to immune rejection after transplantation, thus offering major advantages over other pluripotent cell sources of hepatocytes. In the paper, we demonstrated that hepatocytes derived from hpSCs in this differentiation system demonstrate activities that are missing in a number of metabolic liver diseases, such as expression of AAT and OTC genes. Thus, personalized HLA-matching, as well as presence of the required activities make the pure hepatocyte population derived from hpSCs an attractive development candidate for cell therapy of metabolic liver diseases, urea cycle disorders, AAT-deficiency or other liver diseases in which a single hepatocyte product can ameliorate disease."

The approach used to derive a pure hepatocyte population is a technology platform that may allow derivation of various cell populations from different sources.

Andrey Semechkin, Ph.D., President and CEO of ISCO, and co-author of the paper stated, "We have discovered technology that has a number of features and advantages, and our plans are to expand the applications of this platform to develop new products. This system is universal and does not depend of the particularities of cell lines. As such it could be successfully used with hpSCs, hESCs and, we believe, with induced pluripotent stem cells (iPSs). Because isolation of undifferentiated cells happens at the first step of the differentiation procedure, the technology could be used to isolate other cell types, for example pancreatic or heart cells. Also, because technology is based on a natural process, cell separation is accomplished without any cell damage, in contrast to physical purification methods such as FACS, or magnetic sorting."

An electronic pre-copy-edited version of the paper entitled "Derivation of high-purity definitive endoderm from human parthenogenetic stem cells using an in vitro analog of the primitive streak" is available at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct0284agapova.

A color version of the paper will be available when the print publication is issued. Prior to print publication, color figures can be obtained upon request from Nikolay Turovets, PhD:nturovets@intlstemcell.com.

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, the potential production and benefits of stem cell lines, the potential applications and benefits of the new technology, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and new technologies, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation
760-940-6383
Kenneth C. Aldrich
Chairman
kaldrich@intlstemcell.com
or
Nikolay Turovets, Ph.D.
Director of Research and Therapeutic Development
nturovets@intlstemcell.com
or:
Lippert/Heilshorn & Associates
Don Markley (dmarkley@lhai.com)
310-691-7100

Posted in Stem Cells, Stem Cell Therapy | Comments Off

International Stem Cell to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on June 16

Posted: June 19, 2011 at 4:09 pm

International Stem Cell Corporation (OTCBB:ISCOE) announced today that Kenneth Aldrich, Chairman, will present to investors as part of the Lippert/Heilshorn & Associates Life Sciences & Medical Technologies Virtual Conference on Thursday, June 16, 2011 at 10:30 a.m. Eastern.

A webcast of the presentation will be accessible online at http://www.internationalstemcell.com, or the PrecisionIR event site: http://www.vcall.com/CustomEvent/lipper/index.asp. An archived version will be available for 30 days.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

Posted in Stem Cells, Stem Cell Therapy | Comments Off

International Stem Cell Corporation (ISCO) Announces That Donna Queen, Former President and CEO of ZO SKIN HEALTH, the Luxury Brand Created by Zein Obagi, MD, Has Joined ISCO Executive Team

Posted: June 19, 2011 at 4:08 pm

Posted in Stem Cells, Stem Cell Therapy | Comments Off

Page 275«..10 20..274275276 277..280 290..»

Category Archives: Stem Cell Therapy

Kurt May to Join International Stem Cell Corporation as Senior Vice President

Lou Gehrig's Disease (ALS): UCSD Team's Stem Cell Therapy Rationale

TRANSPLANT VIEWS: Stem cell therapy used for diabetic patients

Stem Cell Therapy for Multiple Sclerosis (MS patient)

Heart Disease And Cardiac Failure: The Role Of Stem Cells …

Stem Cell Therapy for Stroke – Gary Steinberg, Stanford University

International Stem Cell Corporation (ISCO) Announces That Donna Queen, Former President and CEO of ZO SKIN HEALTH, the Luxury Brand Created by Zein Obagi, MD, Has Joined ISCO Executive Team

International Stem Cell Corporation Discovers Method to Produce Uncontaminated Liver Cells: New Platform to Produce Various Cell Types Free From Undifferentiated, Potentially Tumorigenic, Cells

International Stem Cell to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on June 16

International Stem Cell Corporation (ISCO) Announces That Donna Queen, Former President and CEO of ZO SKIN HEALTH, the Luxury Brand Created by Zein Obagi, MD, Has Joined ISCO Executive Team

Categories

Archives

Recommended Sites

Contact Us

Recent Posts